FR2602144A1 - Medicaments against nausea and vomitting - Google Patents

Medicaments against nausea and vomitting Download PDF

Info

Publication number
FR2602144A1
FR2602144A1 FR8709944A FR8709944A FR2602144A1 FR 2602144 A1 FR2602144 A1 FR 2602144A1 FR 8709944 A FR8709944 A FR 8709944A FR 8709944 A FR8709944 A FR 8709944A FR 2602144 A1 FR2602144 A1 FR 2602144A1
Authority
FR
France
Prior art keywords
medicament
amount
dosage unit
rhizoma zingiberis
per dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR8709944A
Other languages
French (fr)
Other versions
FR2602144B1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SCHUPMANN CLAUDIA
Original Assignee
SCHUPMANN CLAUDIA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SCHUPMANN CLAUDIA filed Critical SCHUPMANN CLAUDIA
Publication of FR2602144A1 publication Critical patent/FR2602144A1/en
Application granted granted Critical
Publication of FR2602144B1 publication Critical patent/FR2602144B1/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/76—Salicaceae (Willow family), e.g. poplar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

New medicaments against nausea, vomiting etc. contain (a) rhizoma zingiberis (root ginger) and (b) extr. Ginkgo bilobae E fol. sicc. (extract of dried leaves of Ginkgo biloba).

Description

La présente invention concerne un médicament à base de produits végétaux actif contre les nausées, les vomissements et les troubles analogues.The present invention relates to a medicinal product based on plant products which is active against nausea, vomiting and similar disorders.

Les nausées et les vomissements sont des sympt.ômes qui peuvent être provoqués aussi bien par des processus bénins que par des maladies graves. Les nausées et les vomissements du "mal des voyages sont dus par exemple à une irrigation excessive et irritante du système labyrinthique.Nausea and vomiting are symptoms that can be caused by both mild processes and serious illnesses. Travel sickness nausea and vomiting are caused, for example, by excessive and irritating irrigation of the labyrinthine system.

Certes, certaines personnes sont plus résistantes que d'autres aux effets des formes inhabituelles de mouvement mais en principe tout individu peut souffrir du mal des voyages. I1 existe donc un besoin général important en une prévention des symptômes de cette maladie.Certainly, some people are more resistant than others to the effects of unusual forms of movement, but in principle any individual can suffer from travel sickness. There is therefore an important general need for preventing the symptoms of this disease.

Jusqu'à maintenant, on n'a pas pu expliquer clairement le mécanisme des nausées et des vomissements au cours des premiers mois de la grossesse. Ces symptômes, dans ce cas, sont difficiles à traiter, en partie parce qu'aucune substance active ne semble être efficace à tous égards, mais surtout parce que l'utilisation de médicaments au cours de la grossesse doit être limitée dans la plus grande mesure possible.To date, the mechanism of nausea and vomiting has not been clearly explained during the first months of pregnancy. These symptoms, in this case, are difficult to treat, partly because no active substance seems to be effective in all respects, but above all because the use of drugs during pregnancy must be limited to the greatest extent possible.

Les nausées et les vomissements peuvent également être des phénomènes d'accompagnement du mal de tête du type migraine ou constituer des symptômes de maladies graves telles que l'llypothyréose, la pyélonéphrite, l'appendicite aiguë, la cholécystite, etc.Nausea and vomiting can also be accompanying phenomena of migraine type headache or constitute symptoms of serious diseases such as llypothyreosis, pyelonephritis, acute appendicitis, cholecystitis, etc.

Naturellement, un traitement limité aux symptômes : nausées et vomissements, n'est justifié que dans le cas de causes bénignes ou inexpliquées, ctest-à-dire par exemple dans les cas du mal des voyages, des vomissements de la grossesse ou de la migraine. Au cours de ces dernières années, un anti-émétique à base de Rhizoma Zingiberis a donné de bons résultats dans la prévention des symptômes du mal des voyages. Contre les vomisséments de la grossesse, il n'existait jusqu'à maintenant aucun médicament qui soit à la fois bien efficace et entièrement exempt d'effets secondaires.Naturally, treatment limited to symptoms: nausea and vomiting, is only justified in the case of mild or unexplained causes, that is to say, for example in the case of travel sickness, vomiting of pregnancy or migraine . In recent years, an anti-emetic containing Rhizoma Zingiberis has given good results in the prevention of the symptoms of travel sickness. Against the vomiting of pregnancy, there has so far been no drug that is both effective and completely free of side effects.

On a déjà utilisé avec succès Extr. Ginkgo bilobae e fol.We have already successfully used Extr. Ginkgo bilobae e fol.

sicc. pour le traitement des douleurs dues aux migraines; on signale que chez les patients traités, en plus de la suppression du mal de tête, on a également constaté un sentiment de bien-être général.sicc. for the treatment of migraine pain; it is reported that in treated patients, in addition to the suppression of the headache, there was also a feeling of general well-being.

La présente invention vise à la mise au point d'un médicament actif sur les nausées, les vomissements et les.troubles analogues, en particulier dans le cas de mal des voyages, des vomissements dûs à la grossesse ou du mal de tête du type migraine, médicament qui serait plus efficace que les médicaments connus antérieurement et/ou serait exempt d'effets secondaires et de risques de dépendance.The present invention aims at the development of a drug active on nausea, vomiting and similar disorders, in particular in the case of travel sickness, vomiting due to pregnancy or headache of the migraine type. , drug which would be more effective than the drugs known previously and / or would be free of side effects and risks of dependence.

Ce but a été atteint conformément à ltinvention dans un médicament contenant Rhizoma Zingiberis et Extr. Ginkgo bilobae e fol. sicc. This object was achieved in accordance with the invention in a medicament containing Rhizoma Zingiberis and Extr. Ginkgo bilobae e fol. sicc.

Dans des modes de réalisation particuliers, le médicament selon l'invention contient de 300 à 700 mg, de préférence 500 mg de Rhizoma Zingiberis à l'état de poudre par unité de dosage et, dans le cas où on utilise l'extrait, de 10 à 100 mg, de préférence 50 mg de Rhizoma Zingiberis par unité de dosage, et il contient en outre de 20 à 40 mg, de préférence 30 mg d'Extr. Ginkgo bilobae e fol. sicc. par unité de dosage.In particular embodiments, the medicament according to the invention contains 300 to 700 mg, preferably 500 mg of Rhizoma Zingiberis in powder form per dosage unit and, in the case where the extract is used, 10 to 100 mg, preferably 50 mg of Rhizoma Zingiberis per dosage unit, and it also contains 20 to 40 mg, preferably 30 mg of Extr. Ginkgo bilobae e fol. sicc. per dosage unit.

Dans un autre mode de réalisation particulier, le médicament selon l'invention contient en outre un agent analgésique, par exemple Cortex Salicis ou le Paracétamol; ainsi l'unité de dosage du médicament selon l'invention peut contenir de 200 à 800 mg, de préférence 500 mg, d'un agent analgésique.In another particular embodiment, the medicament according to the invention additionally contains an analgesic agent, for example Cortex Salicis or Paracetamol; thus the dosage unit of the medicament according to the invention can contain from 200 to 800 mg, preferably 500 mg, of an analgesic agent.

Le médicament selon l'invention peut être présenté sous la forme de capsules, de dragées à effet retard ou à effet de dépôt ou sous la forme de composition liquide contenant les deux composants actifs.The medicament according to the invention can be presented in the form of capsules, dragées with delay effect or deposition effect or in the form of liquid composition containing the two active components.

On a constaté que la combinaison selon l'invention des deux substances actives végétales Rhizoma Zingiberis et
Extr. Ginkgo bilobae e fol. sicc. conduisait à un renforcement synergétique surprenant de l'activité des substances actives individuelles observée dans les domaines d'indication antérieurs, ctest-à-dire le mal des voyages dans le cas de Rhizoma Zingiberis et les migraines dans le cas d'Extr. Ginkgo bilobae e fol. sicc. On peut en outre s'attendre à à une meilleure acceptation par les patients car dans les domaines d'indication en question, il fallait absorber au moins deux médicaments. En même temps, on dispose d'un médicament à haute efficacité et parfaite innocuité pour le traitement des nausées et des vomissements de la grossesse.It was found that the combination according to the invention of the two active plant substances Rhizoma Zingiberis and
Extr. Ginkgo bilobae e fol. sicc. led to a surprising synergistic reinforcement of the activity of the individual active substances observed in the previous fields of indication, ie travel sickness in the case of Rhizoma Zingiberis and migraines in the case of Extr. Ginkgo bilobae e fol. sicc. We can also expect better acceptance by patients because in the areas of indication in question, it was necessary to take at least two drugs. At the same time, there is a drug with high efficiency and perfect safety for the treatment of nausea and vomiting of pregnancy.

Outre les indications déjà mentionnées, le médicament selon l'invention est également actif sur les vertiges (dQs à l'âge), les bourdonnements d'oreilles, les défauts de concentration d'esprit ou les troubles analogues. Dans le cas particulier du traitement de la douleur des migraines, l'addition au médicament dtun agent analgésique spécial, par exemple le Paracétamol ou bien, pour se limiter également dans ce cas à des substances actives végétales, Cortex Salicis, a donné des résultats satisfaisants. In addition to the indications already mentioned, the medicament according to the invention is also active on dizziness (dQs at age), ringing in the ears, impaired concentration of mind or similar disorders. In the particular case of the treatment of migraine pain, the addition to the drug of a special analgesic agent, for example Paracetamol or, to be limited also in this case to vegetable active substances, Cortex Salicis, has given satisfactory results. .

On ajoutera que Rhizoma Zingiberis contient des phéna alcanones (gingérols) qui inhibent la biosynthèse des prostaglandines. Il s'agit là d'un second effet du médicament qui jusqutà maintenant, n'a pas encorc été exploité en thérapeutique et qui présente de l'intérêt par exemple pour la mise en valeur des analgésiques de la médecine antérieure.It will be added that Rhizoma Zingiberis contains phena alkanones (gingerols) which inhibit the biosynthesis of prostaglandins. This is a second effect of the drug which until now has not yet been used in therapy and which is of interest, for example, for the development of analgesics from prior medicine.

Une unité de dosage contiendra de préférence environ 30 mg d'Extr. Ginkgo bilobae e fol. sicc et environ 500 mg de Rhizoma Zingiberis dans le cas de l'utilisation de poudre ou 50 mg dans le cas a d'utilisation
Dans le cas d'une combinaison avec un agent analgésique, celui-ci sera présent en quantité de 500 mg par unité de dosage. Une telle unité de dosage pourra être administrée trois fois par jour et, dans les cas les plus sévères, 6 fois par jour.A dosage unit will preferably contain approximately 30 mg of Extr. Ginkgo bilobae e fol. sicc and about 500 mg of Rhizoma Zingiberis in the case of powder use or 50 mg in the case of use
In the case of a combination with an analgesic agent, this will be present in an amount of 500 mg per dosage unit. Such a dosage unit can be administered three times a day and, in the most severe cases, 6 times a day.

La composition peut être à l'état de capsules, de dragées à retard ou de dragées à dépôt, ou à l'état de cooposition liquide des composants.The composition can be in the form of capsules, delay dragees or deposit dragees, or in the liquid co-position of the components.

Les caractéristiques de l'invention peuvent être essentielles individuellement ou en combinaisons quelconques pour la mise en oeuvre de l'invention dans ses divers modes de réalisation. The characteristics of the invention may be essential individually or in any combinations for the implementation of the invention in its various embodiments.

Claims (12)

RevendicationsClaims 1. Médicament actif sur les nausées, les vomissements et les troubles analogues, caractérisé par le fait outil contient Rhizoma Zingiberis et Extr. Ginkgo bilobae e fol. sicc.1. Active drug for nausea, vomiting and similar disorders, characterized by the fact that it contains Rhizoma Zingiberis and Extr. Ginkgo bilobae e fol. sicc. Rhizoma Zingiberis en quantité de 300 à 700 mg par unité de dosage dans le cas où on utilise une poudre.Rhizoma Zingiberis in an amount of 300 to 700 mg per dosage unit in the case where a powder is used. 2. Iédicament selon la revendication 1, qui contient 2. The medicament of claim 1, which contains 3. Médicament selon la revendication 2, qui contient3. The medicament of claim 2, which contains Rhizoma Zingiberis en quantité de 500 mg par unité de dosage.Rhizoma Zingiberis in an amount of 500 mg per dosage unit. 4. Médicament selon la revendication 1, qui, dans le cas d'utilisation d'extrait, contient Rhizoma Zingiberis en quantité de 10 à 100 mg par unité de dosage.4. Medicament according to claim 1, which, in the case of use of extract, contains Rhizoma Zingiberis in an amount of 10 to 100 mg per dosage unit. 5. Médicament selon la revendication 4, qui, dans le cas d'utilisation d'extrait, contient Rhizoma Zingiberis en quantité de 50 mg par unité de dosage.5. Medicament according to claim 4, which, in the case of use of extract, contains Rhizoma Zingiberis in an amount of 50 mg per dosage unit. 6. Médicament selon l'une des revendications 1 à 5, qui contient Extr. Ginkgo bilobae e fol. sicc. en quantité de 20 à 40 mg par unité de dosage.6. Medicament according to one of claims 1 to 5, which contains Extr. Ginkgo bilobae e fol. sicc. in an amount of 20 to 40 mg per dosage unit. 7. Médicament selon la revendication 6, qui contient Extr.7. The medicament of claim 6, which contains Extr. Ginkgo bilobae e fol. sicc. en quantité de 30 mg par unité de dosage.Ginkgo bilobae e fol. sicc. in an amount of 30 mg per dosage unit. 8. Médicament selon l'une des revendications 1 à 7, qui contient en outre un agent analgésique.8. Medicament according to one of claims 1 to 7, which further contains an analgesic agent. 9. Médicament selon la revendication 8, dans lequel agent analgésique est Cortex Salicis ou le Paracétamol.9. The medicament of claim 8, wherein the analgesic agent is Cortex Salicis or Paracetamol. 10. Médicament selon la revendication 8 ou 9, qui contient l'agent analgésique en quantité de 200 à 800 mg.10. The medicament of claim 8 or 9, which contains the analgesic agent in an amount of 200 to 800 mg. 11. Médicament selon la revendication 10, qui contient l'agent analgésique en quantité de 500 mg.11. The medicament of claim 10, which contains the analgesic agent in an amount of 500 mg. 12. Médicament selon l'une des revendications 1 à 11, qui est présenté à l'état de capsules, de dragées à retard ou à dépôt ou d'une composition liquide contenant les deux composants. 12. Medicament according to one of claims 1 to 11, which is presented in the form of capsules, delayed or deposition dragees or a liquid composition containing the two components.
FR8709944A 1986-08-01 1987-07-15 MEDICINAL PRODUCT BASED ON PLANTS, ACTIVE AGAINST NAUSEA, VOMITING AND THE LIKE Expired FR2602144B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19863626128 DE3626128A1 (en) 1986-08-01 1986-08-01 Pharmaceutical composition for nausea, vomiting or the like

Publications (2)

Publication Number Publication Date
FR2602144A1 true FR2602144A1 (en) 1988-02-05
FR2602144B1 FR2602144B1 (en) 1989-06-09

Family

ID=6306515

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8709944A Expired FR2602144B1 (en) 1986-08-01 1987-07-15 MEDICINAL PRODUCT BASED ON PLANTS, ACTIVE AGAINST NAUSEA, VOMITING AND THE LIKE

Country Status (3)

Country Link
JP (1) JPS6341424A (en)
DE (2) DE3626128A1 (en)
FR (1) FR2602144B1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4317868C2 (en) * 1993-05-28 1996-04-18 Arrowdean Ltd Novel anxiolytic
KR20030008446A (en) * 2001-07-18 2003-01-29 정영내 morning sickness relief compositions of which chief ingredient is ginger
RU2670516C2 (en) 2013-03-15 2018-10-23 Марс, Инкорпорейтед Composition and method for preventing, reducing, alleviating or treating idiopathic vomiting
CN118105365A (en) 2013-03-15 2024-05-31 马斯公司 Use of a compound in the manufacture of a medicament for preventing or treating idiopathic vomiting in a companion animal
CN104623594B (en) * 2015-01-09 2018-01-19 李培良 A kind of Chinese medicine composition for treating vomiting and diarrhoea and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS559021A (en) * 1978-07-04 1980-01-22 Kodama Kk Physiologically active substance from japanese ginger, its preparation, and drug comprising it
JPS5683416A (en) * 1979-12-11 1981-07-08 Lion Corp Composition for oral cavity
EP0086315A1 (en) * 1981-12-22 1983-08-24 Prodipharm S.A. Process for the production of vaso-active compounds by extraction of gingko leaves
FR2583640A1 (en) * 1985-06-24 1986-12-26 Berdal Pascal Pharmaceutical compositions for vasculotropic and antisclerotic use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3338995A1 (en) * 1983-10-27 1985-05-09 Dr. Willmar Schwabe GmbH & Co, 7500 Karlsruhe MEDICINAL PRODUCTS CONTAINING BILOBALID

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS559021A (en) * 1978-07-04 1980-01-22 Kodama Kk Physiologically active substance from japanese ginger, its preparation, and drug comprising it
JPS5683416A (en) * 1979-12-11 1981-07-08 Lion Corp Composition for oral cavity
EP0086315A1 (en) * 1981-12-22 1983-08-24 Prodipharm S.A. Process for the production of vaso-active compounds by extraction of gingko leaves
FR2583640A1 (en) * 1985-06-24 1986-12-26 Berdal Pascal Pharmaceutical compositions for vasculotropic and antisclerotic use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN, vol. 4, no. 34 (C-3)[516], 22 mars 1980; & JP-A-55 009 021 (KODAMA K.K.) 22-01-1980 *
PATENT ABSTRACTS OF JAPAN, vol. 5, no. 152 (C-73)[824], 25 septembre 1981; & JP-A-56 083 416 (LION K.K.) 08-07-1981 *

Also Published As

Publication number Publication date
DE3626128A1 (en) 1988-02-04
DE3645254C2 (en) 1994-06-09
JPS6341424A (en) 1988-02-22
DE3626128C2 (en) 1992-12-24
FR2602144B1 (en) 1989-06-09

Similar Documents

Publication Publication Date Title
Cohen et al. Trigeminal autonomic cephalalgias: current and future treatments: CME
JPS63313726A (en) Method and composition for treating nervous disease such as hemicrania by stimulating nervous cell
SG171870A1 (en) A composition for buccal absorption of nicotine for the purpose of smoking cessation
US5612061A (en) Composition and method for the treatment of premenstrual syndrome
EP1001775B1 (en) Medicine containing yohimbine and arginine for treating erectile dysfunction
JP2004534094A (en) Composition effective for hangover and use therefor
FR2602144A1 (en) Medicaments against nausea and vomitting
WO2013186220A1 (en) Compositions comprising hesperidin and/or apigenin i.a. for medical use or for use in treatment of sleeping disorders
US6159986A (en) Compounds and therapy for resisting memory loss in humans
AU768961B2 (en) Pharmaceutically active plant preparation for the treatment of migraine
US20170020946A1 (en) Analgesic compositions and methods of use
JP2007501856A (en) Migraine medication
Igeh et al. Aqueous extract of Erythrina senegalensis exhibits dose-dependent hepatoprotective activity on paracetamol-induced liver damage in wistar rats
Enwonwu Ascorbate status and xerostomia
EP4240387A1 (en) Novel therapeutic composition based on essential oils at low doses
DE102022103658A1 (en) Drug composition containing L-tryptophan (L-Try) and L-5-hydroxytryptophan (5-HTP) and a peripheral degradation inhibitor
EA011926B1 (en) Oral antidepressant formulation comprising acetylsalicylic acid to accelerate onset of action
WO1997038701A1 (en) Composition and method for the treatment of premenstrual syndrome
Samir Kouzi., et al.“An Overview of Clinical Studies of Melatonin as an Effective Migraine Preventive Drug”
Foster Herbal Remedies: Feverfew: When the Head Hurts
FR2649615A1 (en) Composition based on Simarouba glauca, used for the treatment, in particular, of psychological disorders and/or digestive disorders
ATE270095T1 (en) MEDICINAL PRODUCTS FOR USE IN THE MOUTH
JP2002281939A (en) Crude drug food product
FR2647345A1 (en) COMBINATION OF L-5-HYDROXY-TRYPTOPHANE AND BENSERAZIDE AS A PHARMACEUTICAL COMPOSITION, ESPECIALLY USEFUL IN THE TREATMENT OF CEREBELOUS AND OTHER DISORDERS OF BALANCE AND ATAXIA, OF ALL ORIGINS, AND ITS USE FOR THE PREPARATION OF LADITE COMPOSITION
RU2113229C1 (en) Sedative medicinal agent

Legal Events

Date Code Title Description
TP Transmission of property
TP Transmission of property
ST Notification of lapse